Pharmaceutical News

RSS

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Helix BioPharma Corp. today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").

7 Oct 2009

HHS and PEPFAR approve the 100th HIV/AIDS antiretroviral drug

The U.S. Department of Health and Human Services (HHS) today marked today marked the recent approval of the 100th antiretroviral drug in association with the President's Emergency Plan for AIDS Relief (PEPFAR), aimed at the prevention, treatment, and care of people infected with and affected by HIV/AIDS worldwide.

7 Oct 2009

FDA provides Genzyme a complete response letter for Clolar NDA

Genzyme Corporation announced today that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. The agency recommended a randomized, controlled clinical study be conducted for label expansion of Clolar in this indication.

7 Oct 2009

FDA completes inspection of Catalent Pharma's manufacturing facility in Germany

Catalent Pharma Solutions announces that its integrated dose form development, manufacturing and packaging facility in Schorndorf, Germany, has successfully completed an FDA inspection.

7 Oct 2009

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

7 Oct 2009

Research on malarial drugs for travelers

A new review of existing research finds that a combination drug and the common antibiotic doxycycline allow travelers to fend off malaria with the fewest side effects in areas where the parasite is resistant to a widely accepted preventive treatment.

7 Oct 2009

Opioid drugs may not be effective for osteoarthritis

Should you take opioid drugs for hip and knee pain caused by osteoarthritis? Probably not, suggests a new review of the best research on the subject.

7 Oct 2009

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Abatacept, a member of a new class of drug that targets immune cells to treat rheumatoid arthritis (RA), is effective against RA, according to a new Cochrane Systematic Review. The review examines recent trials to assess safety and efficacy of the drug.

7 Oct 2009

Combination of leukemia and breast cancer drugs inhibits cancer progression

When breast cancer spreads or metastasizes, it crashes through the body's protective fences. The disease becomes fatal when it travels outside the mammary ducts, enters the bloodstream and spreads to the bones, liver or brain.

7 Oct 2009

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

Pre-registered and certified providers in the southwest, southeast, and north-central regions of the state have begun to receive the first doses of the live attenuated pandemic H1N1 influenza vaccine, also known by the brand name FluMist, the Pennsylvania Department of Health said today.

7 Oct 2009

Get vaccinated against both H1N1 flu and the seasonal flu, advises Chief Nurse of the American Red Cross

With the first doses of the H1N1 (swine) flu vaccine being shipped and seasonal flu shots underway, people should be getting vaccinations when they can for these flu viruses, said Sharon Stanley, Chief Nurse of the American Red Cross.

7 Oct 2009

PSI-879 nominated as second development candidate for treating HCV infection

Pharmasset, Inc. announced today the nomination of PSI-352879 (PSI-879) as a second development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection.

7 Oct 2009

African leaders gather to discuss ways to bolster continent's drug, diagnostic development

Business Day examines efforts currently underway in Africa to bolster the continent's ability to develop new drugs and diagnostics.

7 Oct 2009

Researchers make breakthrough in finding a vaccine against horse disease strangle

A research group at the Department of Microbiology, Swedish University of Agricultural Sciences (SLU) in Uppsala, Sweden has - in collaboration with J-I Flock's research group at the Karolinska Institutet medical university in Stockholm, the pharmacological company Intervacc AB, Stockholm and the Animal Health Trust in the UK - after many years of research made a breakthrough in finding a vaccine against the horse disease strangle.

7 Oct 2009

iMedicor to market Access Pharmaceuticals' MuGard in North America

ACCESS PHARMACEUTICALS, INC. announced today that it had signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

6 Oct 2009

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

A new treatment option for Canadians with schizophrenia, ABILIFY(TM) (aripiprazole), is now available in Canada. For those living with this lifelong disease who may be struggling with a treatment that doesn't work for them or with side effects that are difficult to tolerate, ABILIFY offers efficacy and good safety and tolerability with limited impact on weight, blood sugar and lipids - significant clinical benefits that may help patients stay on treatment longer.

6 Oct 2009

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL (“Biovail”), a subsidiary of Biovail Corporation.

6 Oct 2009

Pharmaceutical News

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

HHS and PEPFAR approve the 100th HIV/AIDS antiretroviral drug

FDA provides Genzyme a complete response letter for Clolar NDA

FDA completes inspection of Catalent Pharma's manufacturing facility in Germany

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Research on malarial drugs for travelers

Opioid drugs may not be effective for osteoarthritis

Cochrane Systematic Review finds Abatacept effective against rheumatoid arthritis

Combination of leukemia and breast cancer drugs inhibits cancer progression

Pennsylvania to receive first doses of live attenuated pandemic H1N1 influenza vaccine

Get vaccinated against both H1N1 flu and the seasonal flu, advises Chief Nurse of the American Red Cross

PSI-879 nominated as second development candidate for treating HCV infection

African leaders gather to discuss ways to bolster continent's drug, diagnostic development

Researchers make breakthrough in finding a vaccine against horse disease strangle

iMedicor to market Access Pharmaceuticals' MuGard in North America

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

Update from ACADIA Pharmaceuticals regarding its Phase III program with pimavanserin

FDA Advisory Committee approves Peginterferon alfa-2b for treating metastatic melanoma

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Scientia Advisors announces the results of an in-depth study of the changing vaccine industry

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News